Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up
Uveal metastases are the most common intraocular malignancy. The most common primary sites of cancer are from the breast (47%) and lung (21%).1 The treatment for choroidal metastasis depends on many factors including location, multiplicity, and activity of each tumour.1 Bevacizumab (Avastins) is a f...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2006 |
| País: | España |
| Institución: | Universidad Católica de Valencia San Vicente Mártir |
| Repositorio: | RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir |
| Idioma: | inglés |
| OAI Identifier: | oai:riucv.ucv.es:20.500.12466/3678 |
| Acceso en línea: | http://hdl.handle.net/20.500.12466/3678 |
| Access Level: | acceso abierto |
| Palabra clave: | Intraocular malignancy Metastasis 3201.01 Oncología 3201.09 Oftalmología |
| Sumario: | Uveal metastases are the most common intraocular malignancy. The most common primary sites of cancer are from the breast (47%) and lung (21%).1 The treatment for choroidal metastasis depends on many factors including location, multiplicity, and activity of each tumour.1 Bevacizumab (Avastins) is a full-length humanized murine monoclonal antibody against the VEGF molecule, and inhibits angiogenesis and tumour growth.2 In this report, we describe the effect of a single intravitreal injection of bevacizumab (4 mg) in a patient with choroidal metastasis secondary to breast cancer |
|---|